JP2019535262A - キメラ抗原受容体 - Google Patents

キメラ抗原受容体 Download PDF

Info

Publication number
JP2019535262A
JP2019535262A JP2019524412A JP2019524412A JP2019535262A JP 2019535262 A JP2019535262 A JP 2019535262A JP 2019524412 A JP2019524412 A JP 2019524412A JP 2019524412 A JP2019524412 A JP 2019524412A JP 2019535262 A JP2019535262 A JP 2019535262A
Authority
JP
Japan
Prior art keywords
car
nucleic acid
acid sequence
cell
taci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535262A5 (enExample
Inventor
シモビ オヌオハ，
シモビ オヌオハ，
ヴィジャイ ペッダレッディガリ，
ヴィジャイ ペッダレッディガリ，
ルーカス スタンチュク，
ルーカス スタンチュク，
マテュー フェラーリ，
マテュー フェラーリ，
ビアオ マ，
ビアオ マ，
Original Assignee
オートラス リミテッド
オートラス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オートラス リミテッド, オートラス リミテッド filed Critical オートラス リミテッド
Publication of JP2019535262A publication Critical patent/JP2019535262A/ja
Publication of JP2019535262A5 publication Critical patent/JP2019535262A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019524412A 2016-11-11 2017-11-10 キメラ抗原受容体 Pending JP2019535262A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1619097.7 2016-11-11
GB201619097 2016-11-11
PCT/GB2017/053386 WO2018087557A1 (en) 2016-11-11 2017-11-10 Chimeric antigen receptor

Publications (2)

Publication Number Publication Date
JP2019535262A true JP2019535262A (ja) 2019-12-12
JP2019535262A5 JP2019535262A5 (enExample) 2020-10-22

Family

ID=60627955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524412A Pending JP2019535262A (ja) 2016-11-11 2017-11-10 キメラ抗原受容体

Country Status (7)

Country Link
US (1) US20190352409A1 (enExample)
EP (1) EP3538556A1 (enExample)
JP (1) JP2019535262A (enExample)
CN (1) CN110114371A (enExample)
AU (1) AU2017357649A1 (enExample)
CA (1) CA3042613A1 (enExample)
WO (1) WO2018087557A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2015221933B2 (en) 2014-02-27 2019-09-12 Autolus Limited APRIL variants
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
KR20200130324A (ko) 2018-02-23 2020-11-18 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Cd83-결합 키메라 항원 수용체
US20200108098A1 (en) * 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
JP7687952B2 (ja) * 2018-10-01 2025-06-03 アディセット セラピューティクス， インク． 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法
JP7602475B2 (ja) * 2019-03-08 2024-12-18 オートラス リミテッド 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
US12023354B2 (en) 2019-05-31 2024-07-02 Case Western Reserve University Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
US20220324964A1 (en) * 2019-06-04 2022-10-13 The General Hospital Corporation Antibodies and chimeric antigen receptors that target taci
WO2021064718A1 (en) * 2019-10-01 2021-04-08 Case Western Reserve University Targeting b cell activating factor receptor (baff-r) using ligand-based chimeric antigen receptor (car)-t cells
CN112779223B (zh) * 2019-11-08 2024-06-11 浙江煦顼技术有限公司 偶联嵌合抗原受体细胞及其用途
EP4110801A1 (en) * 2020-02-25 2023-01-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
GB202008688D0 (en) * 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
CN114807042B (zh) * 2021-01-22 2024-09-03 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
US11359012B1 (en) 2021-08-27 2022-06-14 Nanjing Kaedi Biotherapeutics Ltd. Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2015052538A1 (en) * 2013-10-10 2015-04-16 Ucl Business Plc Chimeric antigen receptor
WO2015075470A1 (en) * 2013-11-21 2015-05-28 Ucl Business Plc Cell
WO2017011804A1 (en) * 2015-07-15 2017-01-19 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
CA2438682A1 (en) * 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
JP2008501621A (ja) * 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
SG10201913682QA (en) * 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
EP4353750A3 (en) * 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2015052538A1 (en) * 2013-10-10 2015-04-16 Ucl Business Plc Chimeric antigen receptor
WO2015075470A1 (en) * 2013-11-21 2015-05-28 Ucl Business Plc Cell
WO2017011804A1 (en) * 2015-07-15 2017-01-19 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy

Also Published As

Publication number Publication date
CN110114371A (zh) 2019-08-09
EP3538556A1 (en) 2019-09-18
US20190352409A1 (en) 2019-11-21
WO2018087557A1 (en) 2018-05-17
CA3042613A1 (en) 2018-05-17
AU2017357649A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
JP2019535262A (ja) キメラ抗原受容体
JP6979423B2 (ja) キメラサイトカイン受容体
JP7253020B2 (ja) キメラ抗原受容体およびその使用
CN107406517B (zh) 包含cd19结合域的嵌合抗原受体(car)
AU2022200052A1 (en) Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
US12187769B2 (en) Cell
CN107208047B (zh) 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
KR20200039793A (ko) Bcma에 결합하는 키메릭 항원 수용체(car) 및 그의 용도
JP2019052190A (ja) キメラ抗原受容体
JP2018518972A (ja) 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞
JP2020537521A (ja) 細胞
CN111479918A (zh) 细胞
CN115768464A (zh) 产生工程化记忆样nk细胞及其组合物的方法
JP2025505546A (ja) キメラｉｌｔ受容体組成物及び方法
WO2021244626A1 (zh) 靶向cldn18.2的嵌合抗原受体及其用途
JP2023524132A (ja) 細胞
US20220267420A1 (en) Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
JP7057975B2 (ja) 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球
US20230183351A1 (en) A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammal
JP2024539281A (ja) キメラサイトカイン受容体
CN115704039A (zh) 包含编码抗原结合分子的多核苷酸和靶向ecm试剂的多核苷酸的多核苷酸及修饰细胞
EP4382119A1 (en) A kit for use in the treatment of hematological cancer
HK40001773A (en) Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220601